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Bone and skeletal muscle mass are highly correlated in mam-
mals, suggesting the existence of common anabolic signaling
networks that coordinate the development of these two anatom-
ically adjacent tissues. The activin signaling pathway is an
attractive candidate to fulfill such a role. Here, we generated
mice with conditional deletion of activin receptor (ACVR) type
2A, ACVR2B, or both, in osteoblasts, to determine the contri-
bution of activin receptor signaling in regulating bone mass.
Immunohistochemistry localized ACVR2A and ACVR2B
to osteoblasts and osteocytes. Primary osteoblasts expressed
activin signaling components, including ACVR2A, ACVR2B,
and ACVR1B (ALK4) and demonstrated increased levels of
phosphorylated Smad2/3 upon exposure to activin ligands.
Osteoblasts lacking ACVR2B did not show significant changes
in vitro. However, osteoblasts deficient in ACVR2A exhibited
enhanced differentiation indicated by alkaline phosphatase
activity, mineral deposition, and transcriptional expression of
osterix, osteocalcin, and dentinmatrix acidic phosphoprotein 1.
To investigate activin signaling in osteoblasts in vivo, we ana-
lyzed the skeletal phenotypes of mice lacking these receptors in
osteoblasts and osteocytes (osteocalcin-Cre). Similar to the lack
of effect in vitro, ACVR2B-deficient mice demonstrated no sig-
nificant change in any bone parameter. By contrast, mice lack-
ing ACVR2A had significantly increased femoral trabecular
bone volume at 6 weeks of age. Moreover, mutant mice lacking
both ACVR2A and ACVR2B demonstrated sustained increases
in trabecular bone volume, similar to those in ACVR2A single
mutants, at 6 and 12 weeks of age. Taken together, these
results indicate that activin receptor signaling, predomi-
nantly through ACVR2A, directly and negatively regulates
bone mass in osteoblasts.
Themusculoskeletal system evolved inmammals to perform
diverse functions that include locomotion, breathing, protect-
ing internal organs, and coordinating global energy expendi-
ture. After the third decade of life, muscles and bones begin to
lose their mass, leading to unfavorable alterations in their func-
tion. Aging is universally accompanied by the loss of bone
(osteopenia) and skeletal muscle (sarcopenia), which together
constitute important global medical problems. Sarcopenia
results in reduced walking speed, poor balance, and instability
that together predispose to falls and fractures. Thus, the coex-
istence of osteoporosis and sarcopenia severely compounds the
problem of frailty in the elderly population (1).
During organogenesis, muscle and bone develop in close
association from common mesodermal precursors and accu-
mulate their final adult mass according to specific genetic
instructions and environmental cues. Bone forms in a discrete
stepwise process: mesenchymal precursors, derived from the
mesoderm, first migrate to the future sites of bone where they
condense. Following condensation, these precursors differenti-
ate into chondrocytes or osteoblasts to form cartilage or bone,
respectively, depending upon positional cues (2). Once formed,
the skeleton is continually remodeled throughout life. These
processes of modeling and remodeling are achieved by the
actions of osteoblasts and osteoclasts, and are coordinated
through the actions of many autocrine/paracrine factors
including Wnts, Hedgehogs, Notch, bone morphogenetic pro-
tein (BMP)2 family members, transforming growth factor-
(TGF-) family members, insulin-like growth factor-1, fibro-
blast growth factor-2 (FGF-2), and interleukin-6 (IL-6), among
others (3). This developing skeleton becomes encased inmuscle
tissue, which matures along with the adjacent modeling skele-
ton (4–6). Similar to the regulation of bone development and
maintenance of mass, skeletal muscle development and main-
tenance is regulated by morphogens and growth factors, many
of which overlap with those involved in skeletogenesis, such as
FGFs, insulin-like growth factor-1, and TGF- (7).
Among themost important factors controllingmuscle devel-
opment is the activin/myostatin family of molecules. Activin,
and closely related inhibin, are members of the TGF- super-
family ofmolecules (8–10) first discovered over 70 years ago (8,This work was supported by the NIAMS National Institutes of Health GrantsR01AR062074 (to D. J. D.) and R01AR060636 (to S.-J. L.). The authors
declare that they have no conflicts of interest with the contents of this
article. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
1 To whom correspondence should be addressed: 601 N. Caroline St., JHOC
5252, Baltimore,MD21287. Tel.: 410-502-6394; E-mail: ddigiro2@jhmi.edu.
2 The abbreviations used are: BMP, bone morphogenetic protein; ACVR,
activin receptor; BV, bone volume; TV, tissue volume; CT, computed
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10–14). Like other TGF- family members, activin and inhibin
are produced as large precursors containing a signaling domain,
a propeptide, and a mature C-terminal segment that possesses
biological activity. Following cleavage of the propeptide, the
structure of functional activin and inhibin is a disulfide linked
C-terminal dimer. In the case of activin, this dimer consists
of two  subunits and for inhibin, one  and one  subunit,
which are encoded by distinct genes (8). Myostatin (previ-
ously GDF-8)was discovered subsequently in a screen for novel
TGF- family members (15). Although structurally similar to
other TGF- family members, its expression is restricted
almost entirely to skeletal muscle, where it functions as a neg-
ative regulator of muscle growth (15). All three of these mole-
cules function through serine/threonine kinase activin recep-
tors that resemble other TGF- family receptors. Type II
receptors are responsible for ligand binding, which can be tem-
pered by soluble endogenous inhibitors (e.g. follistatin), and
type I receptors mediate signal transduction (16–20). Tissue
specificity and activity is regulated at multiple levels in the sys-
tem, including the spatiotemporal expression patterns of vari-
ous components and distinct combinations of receptor/ligand
binding.
Myostatin negatively regulates skeletal muscle develop-
ment by activating ACVR2B and initiating Smad2/3 signal-
ing. Smad2/3 can then activate the MAPK pathway to inhibit
proliferation through the p21/Rb cascade (21, 22), or directly
affect MyoD by sequestering it in the nucleus, thus halting dif-
ferentiation (23). The importance of the myostatin/activin
superfamily in skeletal muscle development is dramatically
illustrated by the grotesque “double muscled” phenotype seen
in myostatin null animals (15) or in mice carrying global muta-
tions in Acvr2a and Acvr2b (24). These receptors appear to
serve redundant functions in skeletal muscle, as heterozygous
loss of Acvr2b in combination with homozygous loss of Acvr2a
results in further increases in muscle mass. Additional studies
using pharmacologic approaches to block access of myostatin
to its receptor also support the importance of this pathway in
regulating muscle development and size (24–27). In each of
these genetic and pharmacologic models, the anabolic effects
on muscle are achieved by inhibition of the inhibitory effect of
myostatin on myoblast proliferation (21, 22) and terminal dif-
ferentiation (23).
Mice and humans that develop largemuscles also form large,
dense bones, and the maintenance of bone and muscle mass is
tightly coupled in both healthy (28–30) and disease states (31).
Conversely, reduced bone mass is commonly associated with a
number of myopathies including Pompe disease (32), multiple
sclerosis (33), and spinal muscular atrophy (34). These obser-
vations suggest the possibility that common signaling networks
control both skeletal muscle and bone development and per-
haps enable these adjacent tissues to develop in synchrony. Pre-
vious studies have shown indirect evidence that the effects of
activin receptor signaling are shared within the musculoskele-
tal system and may also affect bone mass. In support of this
notion, myostatin-deficient mice not only exhibit dramatic
increases in muscle mass but also significant increases in bone
volume (35–38). Additionally, activin/myostatin decoy recep-
tor administration has been shown to cause anabolic changes in
both the muscle and bone compartments (39–41). Recent
studies also suggest that the increases in bone volume after
decoy receptor treatment are a direct effect and independent
from muscle changes (42). Moreover, the anabolic effects of
activin signaling blockade on the skeleton do not appear to be
mediated by myostatin. Treatment with a myostatin-specific
neutralizing antibody did not yield significant bone changes
despite drastic increases in muscle mass (43). Additionally,
decoy receptor administration in myostatin null mice demon-
strated significant increases in bone volume without dramatic
increases in muscle mass (43).
Taken together, studies to date unequivocally show that inhi-
bition of activin ormyostatin signaling in skeletalmuscle, either
by genetic or pharmacological means, increases both muscle
and bone mass. However, whether the bone anabolic effects
seen in these models is due to direct actions on osteoblasts or,
alternatively, results indirectly through changes brought about
by increased muscle mass remains unclear. It is this question
that we aimed to investigate in the current study.
Results
Soluble activin type II receptors increase bonemass in vivo
and osteoblast differentiation in vitro
To begin to investigate the role of activin receptor signaling
within the musculoskeletal system, we first determined the
effects of systemic inhibition of activin receptor signaling
through intraperitoneal injections of ACVR2A/Fc and ACVR2B/
Fc. Consistent with previous reports, after just 4 weeks of solu-
ble activin receptor treatment, there were significant increases
in all wet muscle weights in both receptor treatment groups
(Fig. 1A). ACVR2A/Fc-treated mice showed approximately
double the bone volume fraction and25% increase in cortical
thickness (Fig. 1B). ACVR2B/Fc-treatedmice nearly tripled tra-
becular bone volume, with no significant changes in cortical
thickness (Fig. 1C). To begin to tease out whether these skeletal
anabolic effects were direct or resulted through increasedmus-
cle force or due to release of excess humoral factors following
the increase in muscle mass, we also examined calvarial bone
volume, a skeletal site that is both non-load bearing and rela-
tively isolated from surrounding musculature. Calvarial bone
volumewas significantly increased following both ACVR2A/Fc
and ACVR2B/Fc treatment (Fig. 1D). To further demonstrate
that soluble activin receptors affect osteoblasts directly, we
then performed in vitro studies in primary osteoblasts using
ACVR2B/Fc to exploit its broad binding affinity for ligands.
Here, ACVR2B/Fc administration reduced basal levels of phos-
phorylated SMAD2 (Fig. 1E). Furthermore, ACVR2B/Fc (50
ng/ml)-treated osteoblasts demonstrated modest yet consis-
tent increases in alkaline phosphatase andAlizarin Red staining
(Fig. 1F). Taken together, these experiments strongly suggest
that the anabolic effects of activin receptor signaling blockade
observed in the skeleton are due to direct effects on bone cells,
particularly osteoblasts.
Activin receptor signaling components are expressed and
functional in osteoblasts
We next surveyed the transcriptional expression of the com-
ponents of activin receptor signaling in differentiated osteo-
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blast cultures and compared these results to skeletal muscle, a
tissue in which the function of this pathway is well established.
Activin type II receptorswere expressed in differentiated osteo-
blasts, with ACVR2A expression at levels equal to skeletal mus-
cle and ACVR2B at significantly lower, near negligible, levels in
osteoblasts as comparedwithmuscle. The cognate type I recep-
tor to the activin type II receptors (ACVR1B/ALK4) and the
monomeric components of activin ligands (InhBA and InhBB)
were also highly expressed in differentiated osteoblasts (Fig.
2A). Further supporting the notion that activin signaling is
important for osteoblast function, the expression of activin
receptors also increased throughout the course of osteoblast
differentiation, particularly for ACVR2A (Fig. 2B). It should
also be noted that, despite the 2-fold increase in ACVR2B dur-
ing osteoblast differentiation, its expression remained orders of
magnitude lower than ACVR2A. Expression of ACVR2A and
ACVR2B (Fig. 2C) was also evident in vivo and localized to
osteoblasts and osteocytes within the cortical and trabecular
bone by immunohistochemistry. Finally, functionality of
activin receptor signaling in osteoblasts was demonstrated in
Figure 1. Soluble activin receptor administration increases bone volume in vivo and enhances osteoblast differentiation in vitro. ACVR2A/Fc and
ACVR2B/Fc treatment demonstrates significant increases in skeletalmuscleweights as comparedwith vehicle-treated controls (A). ACVR2A/Fc administration
exhibits a near doubling in trabecular bone volume/tissue volume and a significant increase in cortical thickness (B). Similarly, ACVR2B/Fc treatment demon-
strates a near tripling in trabecular bone volume/tissue volume but no significant increase in cortical thickness (C). Both ACVR2A/Fc and ACVR2B/Fc treatment
demonstrate significant increases in calvarial bonevolume (D). ACVR2B/Fc treatment showsadose-dependent reductionof Smad2phosphorylation in vitro (E).
Further in vitro analysis demonstrates that ACVR2B/Fc treatment enhances alkaline phosphatase activity and mineral deposition by Alizarin Red staining in
osteoblast differentiation cultures (F). *, p 0.05.
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vitro by phosphorylation of Smad2 following activin ligand
(Activin A, AB, or B) treatment (Fig. 2D). These experiments
indicate that the activin type II receptors, predominantly
ACVR2A, are expressed and functional within the osteoblast in
vivo and in vitro.
Disruption of ACVR2A enhances osteoblast differentiation in
vitro
To next determined the role of activin receptor signaling in
osteoblast function, we differentiated primary calvarial osteo-
blasts from either ACVR2A- or ACVR2B-floxed neonates and
deleted the receptors using an adenoviral vector expressing the
Cre recombinase. Proliferation, as assessed by BrdU incorpora-
tion, demonstrated a slight decrease in ACVR2A osteoblasts
(Fig. 3A), whereas ACVR2B osteoblasts demonstrated no sig-
nificant change (Fig. 3B). ACVR2B osteoblasts were unaf-
fected in other functional assays as well, demonstrating no dif-
ference in alkaline phosphatase activity (Fig. 3E) or mineral
deposition (Fig. 3F). However, differentiated osteoblasts lack-
ing ACVR2A did show dramatic increases in alkaline phos-
phatase staining (Fig. 3C) as well as enhanced matrix miner-
alization by Alizarin Red staining (Fig. 3D). In accord with
these functional assays, transcriptional expression of osteo-
blast markers such as Osterix, Osteocalcin, and DMP1 were
significantly up-regulated at Day 7 in ACVR2A osteoblasts
(Fig. 3G). Together, these data demonstrate that disruption
of ACVR2A enhances osteoblast differentiation and matura-
tion in vitro.
Figure 2. Activin receptor signaling components are expressed and functional in osteoblasts. Transcriptional expression assays demonstrate that the
activin signaling components are expressed in primary osteoblasts as compared with skeletal muscle (A). ACVR2A and ACVR2B increase transcriptional
expression with osteoblast differentiation (B). Immunohistochemistry localizes ACVR2A (white arrowheads, left) and ACVR2B (white arrowheads, right) to
osteoblasts andosteocytes in bone sections (C). Phosphorylation of Smad2 following activin ligand administrationdemonstrates activin receptor functionality
in osteoblasts (D).
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ACVR2Amice demonstrate increased bone volume
To determine the consequence of osteoblast-specific disrup-
tion of ACVR2A in vivo, mice lacking ACVR2A within the
osteoblast lineage were generated by crosses of Oc-Cre-
Tg; ACVR2Aflox/flox with ACVR2Aflox/flox mice. Transgenic
ACVR2Aflox/flox mice carrying Oc-Cre (ACVR2A) were
Figure 3. DisruptionofACVR2Aenhancesosteoblast differentiation in vitro.ACVR2Aosteoblasts exhibit a slight decrease in proliferation (A), whereas disrup-
tionof ACVR2Bdoes not alter osteoblast proliferation (B). Osteoblast differentiation is significantly enhancedwithACVR2Adisruption as shownby increased alkaline
phosphatase activity (C) and mineral deposition (D). ACVR2B disruption does not affect alkaline phosphatase activity (E) or mineral deposition (F). Disruption of
ACVR2A induces increased transcriptional expression of osteoblast differentiationmarkers such asOsterix,Osteocalcin, andDmp1 at day 7 (G). *, p 0.05.
Activin signaling in osteoblasts
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born within the expected Mendelian ratios and had normal
lifespans. Allele-specific PCR was performed to confirm that
recombination occurred only within skeletal tissues (Fig. 4A).
Micro-CT analysis of the distal femur revealed that ACVR2A
malemice at 6weeks of age exhibited increased trabecular bone
volume/tissue volume (BV/TV) (34.2  4.1%) and trabecular
number (24.1  1.9%). Furthermore, 12-week-old male
ACVR2A mice demonstrated sustained increases in femoral
trabecular bone volume fraction (47.9  5.4%), trabecular
thickness (13.3 0.7%), trabecular number (27.8 1.7%), and
decreases in trabecular spacing (6.2  0.1%) (Fig. 4, C–F).
Cortical parameters within these males were not significantly
changed at 6 weeks of age. However, at 12 weeks of age, the
ACVR2A male mice demonstrated increases in tissue area
(13.0 0.4%), bone area (15.9 0.7%), polarmoment of inertia
(31.6 0.3%), and cortical thickness (8.6 0.3%) (Fig. 4, G–J).
Similar changes, albeit of lesser magnitude, were observed in
female mice at 6 and 12 weeks of age (data not shown). Histo-
morphometric analysis of the contralateral distal femur from
malemice confirmed the increase in trabecular bone volume in
ACVR2A mice at 6 and 12 weeks of age (Table 1). Surpris-
ingly, there were no significant changes in osteoblast or oste-
oclast numbers, nor dynamic parameters, suggesting the cellu-
lar changes that lead to increased bone volume in ACVR2A
mice likely occurred much earlier in development. Overall,
these findings demonstrate that ACVR2A in osteoblasts acts as
an important negative regulator of skeletal mass in mice.
ACVR2Bmice exhibit no skeletal changes
Despite exhibiting no effect on osteoblasts in vitro, we fur-
ther explored whether ACVR2Bmay behave differently in vivo,
as it was identified in osteoblasts by immunohistochemistry.
We disruptedACVR2B in the osteoblast lineage using the same
osteocalcin-driven Cre by crossing Oc-Cre-Tg; ACVR2Bflox/flox
with ACVR2Bflox/flox mice. Transgenic ACVR2Bflox/flox mice
carrying Oc-Cre (ACVR2B) were born within the expected
Mendelian ratios and with normal lifespans. Allele-specific
PCR was performed to confirm that recombination occurred
Figure 4. Femurs of ACVR2A male mice exhibit increased bone volume. Allele-specific PCR demonstrates ACVR2A (A) and ACVR2B (B) recombination
exclusively at skeletal sites. Femurs fromACVR2Amice exhibit increases in trabecular bone parameters (C–F), including bone volume/tissue volume (C) and
trabecular number (E) at 6 weeks of age. Femurs of ACVR2A mice at 12 weeks of age demonstrate increases in trabecular bone volume/tissue volume (C),
trabecular thickness (D), trabecular number (E), and a decrease in trabecular spacing (F). Femoral cortical parameters (G–J) were unchanged at 6 weeks of age
in ACVR2A mice. However, cortical tissue area (G), bone area (H), and cross-sectional thickness (J) were increased, whereas cortical bone area/tissue area (I)
was unchanged at 6 and 12 weeks of age. *, p 0.05; **, p 0.005.
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only within skeletal tissues (Fig. 4B). Micro-CT analysis of the
distal femur of ACVR2B male mice showed virtually no
changes at 6 and 12 weeks of age (Fig. 5), suggesting that
ACVR2B does not function as the primary receptor for activin
signaling in the osteoblast lineage.
CompoundACVR2A/2Bmice exhibit a skeletal phenotype
similar toACVR2Amice
To unequivocally determine whether ACVR2B is able to
function in osteoblasts in vivo, specifically, to partially compen-
sate for the loss of ACVR2A, we generated compound mutants
of ACVR2A and ACVR2B (ACVR2A/2B) in the osteoblast
lineage by crossing Oc-Cre-Tg; ACVR2A/2Bflox/flox with
ACVR2A/2Bflox/flox mice. ACVR2A/2B male mice showed
significant increases in trabecular bone volume fraction (22.6
1.1%), trabecular number (25.0 3.9%), and decreased trabec-
ular spacing (15.1  3.6%) at 6 weeks of age. At 12 weeks
of age, ACVR2A/2B male mice demonstrated sustained
increases in trabecular bone volume fraction (24.8 2.2%) and
trabecular number (18.4 6.0%) (Fig. 6,A–D). However, unlike
ACVR2A mice, the ACVR2A/2B mice demonstrated no
significant changes in cortical parameters at 12 weeks of age
(Fig. 6, E–H). As was the case for ACVR2A mice, female
ACVR2A/2Bmice displayed skeletal changes similar tomales
with slightly lesser magnitude (not shown). These data demon-
strate that compound ACVR2A/2B mutant mice have
increases in trabecular bone parameters similar to ACVR2A
mutants, further supporting the notion that ACVR2A is the
predominant activin signaling receptor in osteoblasts.
Skeletal changes inACVR2Amice are accompanied by
increasedmechanical attributes
An important consideration for future therapeutic targeting
of this pathway in bone is whether the additional bone mass
observed in the mutant mice is mechanically competent. Thus,
we also evaluated changes in mechanical properties of femurs
fromACVR2Amalemice by three-point bending.ACVR2A
mutants demonstrated significant increases in the ultimate
moment (24.8  2.0%) and bending rigidity (30  2.7%) with
nonsignificant trends in ultimate stress (10.1 0.5%). In addi-
tion, pre-yield parameters including strain (21.3  1.6%),
energy (45.8  6.3%), and toughness (36.1  4.0%) were also
significantly increased compared with controls (Fig. 7, A–G).
The ultimate bending energy and Young’s modulus were, how-
ever, unchanged (Fig. 7, D and H, respectively). Overall, the
mechanical testing indicates that the additional bone produced
in mice with osteoblast-specific disruption of ACVR2A is of
high mechanical competency and increases bone strength.
Activin receptor signaling in osteoblasts contributes
significantly to the anabolic effects observedwith soluble
receptor administration
Finally, we returned to the question ofwhat proportion of the
anabolic effect observed from soluble activin receptor treat-
ment results from direct effects on the osteoblast versus indi-
rect effects from skeletalmuscle, or perhaps even other second-
ary systems. To do so, we treated ACVR2A/2B mutant mice
with ACVR2B/Fc for 4 weeks, as done in our initial experi-
ments, and compared the percentage change in bone volume
with that observed in wild type mice treated with the soluble
receptor. In wild type animals treated with ACVR2B/Fc, the
trabecular bone volume fraction increased by 114 16.0%. By
contrast, ACVR2A/2B mice treated with ACVR2B/Fc gained
62.3 14.5% in trabecular BV/TV (Fig. 8A). Similarly, increases
in trabecular number were differentially affected between con-
trol (82.0 8.5%) and ACVR2A/2B (50.1 11.1%) mice (Fig.
8C). In contrast to the changes observed in trabecular bone,
there were no differential increases in muscle mass (gastrocne-
mius, tibialis anterior, and quadriceps) between control and
ACVR2A/2B mice with ACVR2B/Fc administration (Fig. 8,
Table 1
Bone histomorphometry
6 weeks 12 weeks
Control ACVR2A Control ACVR2A
BV/TVa 5.09 0.28 6.28 0.57b 7.87 0.57 9.99 0.77b
Tb.Th 18.56 0.48 20.88 1.14 22.83 0.90 25.70 1.14b
Tb.Sp 356.18 22.68 323.32 19.59 275.55 16.18 239.75 14.45b
OV/BV 0.99 0.23 0.86 0.07 0.33 0.05 0.51 0.07b
OS/BS 4.17 0.74 3.48 0.27 2.54 0.42 3.18 0.38
O.Th 2.28 0.25 2.53 0.19 1.60 0.15 2.06 0.09b
N.Ob/BS 254.44 39.35 237.30 79.45 144.80 39.62 170.88 65.61
Ob.S/BS 3.68 0.51 2.98 0.90 2.11 0.60 2.44 1.07
ES/BS 2.96 0.61 3.18 0.52 2.15 0.42 2.83 0.62
E.De 5.52 0.46 4.23 0.27b 3.95 0.64 4.15 0.36
N.Oc/BS 95.43 16.49 112.08 19.95 75.73 14.79 93.24 20.41
Oc.S/BS 2.83 0.64 3.00 0.53 2.13 0.42 2.74 0.61
MAR 2.04 0.13 1.71 0.06b 1.13 0.07 1.11 0.07
dLS/BS 9.77 0.83 10.07 1.17 10.65 0.95 12.60 1.68
sLS/BS 7.18 0.61 8.70 1.27 5.97 0.34 5.55 0.66
MS/BS 13.36 0.96 14.42 1.44 13.64 1.07 15.37 1.83
BFR/BS 3.85 0.37 3.41 0.30 3.21 0.35 3.43 0.46
Omt 1.17 0.15 1.47 0.08b 1.47 0.16 1.90 0.13b
Mlt 0.37 0.08 0.37 0.04 0.26 0.04 0.49 0.13b
aHistomorphometry was performed in trabecular bone of the distal femur in ACVR2A male mice. BV/TV, bone volume/tissue Volume (%); Tb.Th, trabecular thickness
(mm); Tb.Sp, trabecular spacing (mm); OV/BV, osteoid volume/bone volume (%); OS/BS, osteoid surface/bone surface (%); O.Th, osteoid thickness (mm); N.Ob/BS, osteo-
blast number/bone surface (no./100 mm); Ob.S/BS, osteoblast surface/bone surface (%); ES/BS, erosion surface/bone surface (%); E.De, erosion depth (mm); N.Oc/BS, oste-
oclast number/bone surface (no./100 mm); Oc.S/BS, osteoclast surface/bone surface (%); MAR, mineral apposition rate (day); dLS/BS, double labeled surface/bone surface
(%); sLS/BS, single labeled surface/bone surface (%); MS/BS, mineralizing surface/bone surface (%); BFR/BS, bone formation rate/bone surface (m3/m2/day); Omt, os-
teoid maturation time (day); Mlt, mineralization lag time (day). Values shown are mean S.E.
b p 0.05 versus age-matched control.
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E–G). Taken together, these data would suggest that a substan-
tial portion of the effect of soluble activin receptor administra-
tion on bone volume (50%) results from the direct actions of
this pathway in osteoblasts.
Discussion
We have described, for the first time, a role for activin recep-
tor signaling in osteoblasts that is analogous to the known func-
tion of this pathway as a negative regulator of muscle develop-
ment and mass. Curiously, early studies suggested that activin
A exerted a stimulatory effect on osteoblastogenesis (44, 45),
but more recent reports using human osteoblast preparations
suggest that activin inhibits osteoblastogenesis andmineraliza-
tion (46). Initial in vivo studies in bonewere also conflicting. For
example, local injection of activinA into rat fibula fractures (47)
or over the calvaria of rat neonates (48) increased bone accu-
mulation. In more recent studies, systemic infusion with a sol-
uble ACVR2A resulted in increased bone mass in both mice
(39) andmonkeys (41, 49). Moreover, administration of soluble
ACVR2A increasedmarkers of bone formation in humans (50).
Histomorphometric analysis of bones from mice and monkeys
treated with this ACVR2A fusion peptide demonstrated that
the anabolic effects were attributable to increased osteoblast
activity (39, 41). Our initial studies with soluble activin receptor
administration support these previous studies of pharmaco-
logic blockade of activin signaling, even over the considerably
shorter course of treatment we used. We utilized this 4-week
treatment in hopes of minimizing the effect of long-term adap-
tation of bone mass in response to the increased mechanical
forces that follow the additional muscle mass gained from sys-
temic activin receptor blockade. Combined with the observed
increases in bone mass in the calvarium, a skeletal site that is
neither load bearing nor encased in skeletal muscle like the
femur, we were encouraged to further investigate the direct
activity of this pathway in osteoblasts.
Further interrogation of this pathway in osteoblasts, both
through pharmacologic and genetic blockade of activin recep-
tor activity, demonstrated that activin receptor signaling is,
indeed, a negative regulator of osteoblast function. Interest-
ingly, both in vitro and in vivo, this effect appears to be nearly
entirely dependent on ACVR2A. Previous studies have sug-
gested that myostatin and/or ACRV2B may also play a role in
regulating bone mass. For example, myostatin null mice have
increased bone mass (35), and infusion of a soluble ACVR2B
fusion molecule increased bone mass in a mouse model of
androgendeprivation (51). In our hands, aswell, administration
of solubleACVR2B resulted in profound increases in trabecular
bone volume. However, we consider it unlikely that ACVR2B
andmyostatin are physiologically relevant in osteoblasts to reg-
ulate bone mass for the following reasons. In the case of the
myostatin null mice, increased bone mass was only observed in
the regions of long bones immediately adjacent to entheses
(35), strongly suggesting that the effect is secondary to
increased mechanical force generated as a result of the double-
muscled phenotype in myostatin null mice. Additionally, we
observed no detectable expression of myostatin in primary
mouse osteoblasts, andACVR2Bexpressionwas orders ofmag-
Figure5.ACVR2Bdisruptiondoesnotaffectbonevolume in vivo.FemursofACVR2Bmalemice shownosignificant changes in trabecular (A–D) or cortical
bone parameters (E–H) at 6 or 12 weeks of age. Trabecular bone parameters include bone volume/tissue volume (A), trabecular thickness (B), trabecular
number (C), and trabecular spacing (D). Apart from a slight reduction in bone area/tissue area at 6 weeks of age (G), there are no significant changes observed
in cortical parameters, including tissue area (E), bone area (F), bone area/tissue area (G), and cross-sectional thickness (H) in 6- or 12-week-old ACVR2Bmale
mice. *, p 0.05.
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nitude lower than ACVR2A expression (Fig. 2A). Finally,
whereas ACVR2B and various soluble forms of this receptor do
predominantly bind and sequester myostatin, ACVR2B is the
more promiscuous of the two activin receptors and also binds
many ligands including activins with nearly as high affinity as it
binds myostatin (52).
Our studies with genetic disruption of ACVR2A and
ACVR2B in osteoblasts bear out the notion that ACVR2A func-
tions as a negative regulator of osteoblast function. Both in vitro
and in vivo, disruption of ACVR2B had no discernable effect on
osteoblast function. Moreover, compound mutants that lacked
both activin receptors in osteoblasts displayed changes in tra-
becular bone that were strikingly similar toACVR2Amice.Of
interest, however, was the fact that the increased cortical bone
phenotype observed inACVR2Amice at 12 weeks of age (Fig.
4, G–J) was not observed in the double ACVR2A/2B mice
(Fig. 6, E–H). One possible explanation for this change, which
presumably, is exactly the opposite of what one would expect if
ACVR2Bwere able to partially compensate forACVR2A loss, is
that complete loss of type II activin receptors from osteoblasts
alters other TGF- family and/or BMP signaling in osteoblasts,
as these receptor families are well known to be promiscuous in
ligand-binding and signaling activity. In support of this notion,
Lowery and colleagues (53) have recently demonstrated that
selective disruption of BMPR2 in osteoprogenitor cells actu-
ally impaired activin signaling, with no effect on BMP signal-
ing, resulting in a high bone mass phenotype. Their result
also indirectly supports our overall finding that activin
receptor signaling in osteoblasts acts as a negative regulator
of their function.
Figure 6. Femurs of ACVR2A/2B mice exhibit similar changes in bone volume as ACVR2A mice. Femurs of ACVR2A/2B male mice exhibit similar
increases in trabecular bone parameters (A–D) as ACVR2A mice. ACVR2A/2B mice demonstrate increases in trabecular bone volume/tissue volume (A),
trabecular number (C), and a decrease in trabecular spacing (D) at 6weeks of ago. These increaseswere sustained in trabecular bone volume/tissue volume (A)
and trabecular number (C) at 12 weeks of age. However, no significant changes were seen in trabecular thickness (B) at 6 or 12 weeks of age. Cortical bone
parameters, including tissue area (E), bone area (F), bone area/tissue area (G), and cross-sectional thickness (H), were unchanged in 6- and 12-week-old
ACVR2A/2B male mice. *, p 0.05.
Figure 7. Skeletal changes in ACVR2A mice are accompanied by
increased mechanical properties. Three-point bending analysis of femurs
from ACVR2Amice demonstrates significant increases in mechanical prop-
erties, such as the ultimate moment (A), bending rigidity (B), pre-yield strain
(E), pre-yield energy (F), and pre-yield toughness (G), and nonsignificant
trends in ultimate stress (C). There were, however, no significant changes in
theultimatebendingenergy (D) or Young’smodulus (H)withACVR2Adisrup-
tion. *, p 0.05.
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Despite the clear skeletal phenotype observed in ACVR2A
mice, we were unable to detect any significant changes in bone
cell numbers at either time point observed, in either sex. We
believe that these changes must have occurred much earlier in
development for a number of reasons. Both genetic and phar-
macologic blockade of activin signaling in vitro resulted in rapid
and robust differentiation of osteoblasts.Wepresume it is likely
that the same effect would have taken place in vivowith an early
burst of osteoblast differentiation and bone formation that was
then damped by yet unknown compensatory mechanisms. In
support of this idea, the only statistically significant histomor-
phometric parameters observed were a slightly repressed min-
eral apposition rate at 6 weeks of age, increased osteoid matu-
ration time at both 6 and 12 weeks of age, and increased
mineralization lag time at 12weeks of age (Table 1); all opposite
of what one would typically expect in mice with higher bone
mass, but consistent with a repression of osteoblast activity.
Future studies are already underway to examine the role of
activin receptor signaling at varying points in the osteoblast
lineage, the current study having focused on the mature osteo-
blast/osteocyte using a human osteocalcin Cre driver, and will
explore these early developmental changes in greater detail.
Regardless, our current study provides clear evidence of the
importance of ACVR2A in osteoblasts as a negative regulator of
bone development and mass.
In an attempt to begin to understand the precise contribu-
tion of activin receptor signaling in osteoblasts to the observed
anabolic effects of soluble activin receptor administration in the
skeleton, we also treated the double ACVR2A/2B mice with
soluble ACVR2B. The results of this experiment suggest that
over half of the observed increase in bone mass following
administration of soluble ACVR2B/Fc is due to the direct activ-
ity of this pathway in osteoblasts (Fig. 8A). Interestingly, the
absolute final trabecular bone volume fraction following solu-
ble receptor treatment was nearly the same between treated
wild type mice and double mutants, suggesting a sort of ceiling
by which modulating this pathway can influence bone volume
inmice (not shown). Interestingly, we observed no difference in
skeletal muscle wet weights between ACVR2B/Fc-treated wild
type and ACVR2A/2B mice, hinting that changes in activin
receptor signaling in osteoblasts do not seem to reciprocally
affect skeletal muscle. The additional increase in bone volume
in ACVR2A/2B mice following ACVR2B/Fc treatment is
likely to occur frommultiple secondary mechanisms, given the
established functions of activin signaling in other systems
known to affect bone, e.g. the pituitary and immune system (54,
55). Other possible mechanisms also include soluble activin
receptors binding to ligands apart from the activins, GDF mol-
ecules, or myostatin, such as the BMP ligands (56, 57). It is
possible that soluble activin receptor administration may also
be affecting BMP signaling, either directly or indirectly through
the removal of ligand competition. Future studies are already
underway to determine the precise contribution of skeletal
muscle to this effect by observing changes in the skeleton fol-
lowing muscle-specific disruption of activin receptor signaling.
Our study is the first to conclusively demonstrate the activity
of activin receptor signaling in osteoblasts as a negative regula-
tor of bone development, analogous to the well established
function of this pathway in skeletal muscle. This effect appears
to be mediated predominantly through ACVR2A and its asso-
ciated ligands, suggesting an evolutionary split in the control of
musculoskeletal development; with ACVR2A and its ligands con-
trolling the skeleton, whereas ACVR2B and myostatin exert con-
trol over skeletal muscle. Such an arrangement would allow for
Figure 8. Activin receptor signaling is a significant contributor to anabolic changes observed with soluble receptor administration. Soluble activin
receptor treatmentwith ACVR2B/Fc demonstrates attenuated increases in bone volume/tissue volume (A), trabecular thickness (B), and trabecular number (C)
in ACVR2A/2B mice. There were no differential changes in trabecular bone spacing (D) or differential increases in skeletal muscle weights, including the
gastrocnemius (E), tibialis anterior (F), or quadriceps (G) muscles. *, p 0.05.
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precise, concertedcontrol of thedevelopment andmaintenanceof
themusculoskeletal system,andalsoprovidesaparticularly attrac-
tive therapeutic area tomodulate cross-talk between both tissues.
Experimental procedures
Soluble activin type II receptor animal studies
All animal protocols were approved by the Johns Hopkins
University Institutional Animal Care and Use Committee. Sys-
temic suppression of activin ligandswas accomplished by intra-
peritoneal injections (10 mg/kg body weight) of a soluble chi-
meric fusion protein consisting of either the extracellular
ACVR2A orACVR2B domain conjugated to the Fc domain of a
murine IgG antibody (ACVR2A/Fc or ACVR2B/Fc, respec-
tively). Injections were administered weekly for 4 weeks in
12-week-old femalemice (n	 5). After soluble activin receptor
treatment, skeletal tissues were harvested and wet muscle
weights were measured.
Transgenic animal studies
Osteoblast-specific disruption of ACVR2A, ACVR2B,
or both was accomplished by crossing ACVR2Aflox/flox or
ACVR2Bflox/flox mice (58), with mice expressing the Cre
recombinase under the direction of the human osteocalcin
promoter (Oc-Cre), in which Cre recombinase expression
is restricted to mature osteoblasts (59). Recombination
within the skeletal tissues was confirmed using allele-spe-
cific PCR and details are available upon request. Con-
trol (ACVR2Aflox/flox or ACVR2Bflox/flox) and mutant
(ACVR2Aflox/flox or ACVR2Bflox/flox; Oc-Cre) male and
female mice were sacrificed at 6 and 12 weeks of age (n 	 10).
Skeletal tissues then were harvested and fixed in formalin over-
night and stored until analysis in 70% ethanol. Prior to harvest,
6-week-old mice were double labeled by two sequential intra-
peritoneal calcein injections (10 mg/kg body weight) at 7 and 2
days prior to sacrifice for dynamic histomorphometric analysis.
Twelve-week-old mice were double labeled with calcein injec-
tions at 10 and 3 days before sacrifice.Miceweremaintained on
a pure C57Bl/6 background.
Microcomputed tomography (CT)
Images of skeletal tissues were obtained using a Skyscan 1172
desktop imaging system (Skyscan-Bruker). Scans were per-
formed with an isotropic voxel size of 10 m at 65 kV and 200
A through a 0.5-mm aluminum filter. Femoral trabecular
parameters were measured in a 200-m region of interest
located 50 m proximal to the distal growth plate. Femoral
cortical parameters were measured within a 500-m region of
interest centered at the midshaft. All bone analysis was per-
formed in accordance with the American Society of Bone and
Mineral Research (ASBMR) recommended parameters (60).
Bone histomorphometry
For histomorphometric analysis, femurs were fixed in 10%
neutral buffered formalin, dehydrated, and embedded in
polymethylmethacrylate. Three-m sections were cut through
the primary spongiosium and stained using the Mason-Gold-
ner Trichrome stain. Additional serial sections were cut for
fluorescent microscopy. Osteoblast and osteoclast measures
were assessed at standardized sites beneath the growth plate
using Osteoplan II (Kontron). Static and dynamic parameters
were calculated in accordance with the ASBMR guidelines (61).
Osteoblast isolation and culture
Osteoblasts were isolated from neonatal calvaria of
ACVR2Aflox/flox and ACVR2Bflox/flox mice by serial digestion in
a 1.8 mg/ml of collagenase type I (Worthington Biochemical)
solution. Calvaria were incubated in 10 ml of collagenase solu-
tion at 37 °C for 15 min with constant agitation per digestion
cycle. The digestion solutions were collected and fresh colla-
genase was added to the remaining digestion cycles an addi-
tional four times. Digestions 3–5, containing osteoblasts,
were pooled and cultured in -minimum essential medium
(-MEM) containing 10% FBS and 1% penicillin/streptomycin.
Osteoblasts were cultured at 37 °C at 5% carbon dioxide in a
humidified incubator. Osteoblasts were grown to 70% conflu-
ence and then transduced in PBS with either a control adeno-
virus encoding green fluorescent protein (GFP) or an adenovi-
rus encoding Cre recombinase (Vector Biolabs) at a titer of 100
multiplicity of infection. After 1 h of incubation, osteoblasts
were supplemented with -MEM containing 10% fetal bovine
serum and 1% penicillin/streptomysin and then allowed to
recover for 48 h. Osteoblasts were then harvested to assess
ACVR2A or ACVR2B deletion efficiency by quantitative PCR
and re-plated for proliferation studies and differentiation
studies.
Osteoblast proliferation and differentiation
Osteoblast proliferation was assessed using BrdU incorpora-
tion and flow cytometry. Osteoblasts were seeded at a low den-
sity (5
 104 cells per well) and cultured in -MEM containing
0.5% FBS for 24 h to arrest cell cycle. BrdU (10 M) (BD Biosci-
ences) was then added to the medium for an additional 24 h
prior to harvest to allow incorporation. Osteoblasts were then
fixed, stained with anti-BrdU antibody and 7-aminoactinomy-
cin D, and analyzed by FACS Calibur flow cytometry (BD Bio-
sciences). 10,000 events were collected for each sample and the
results were processed using Flowing Software version 2.5.
For differentiation experiments, control and ACVR2A or
ACVR2B osteoblasts were cultured to confluence and then
cultured in medium supplemented with 10 mM -glycerol
phosphate and 50g/ml of ascorbic acid. For alkaline phospha-
tase and mineral deposition assays, osteoblasts deficient in
activin receptor were seeded at confluence and subsequently
differentiated in complete medium supplemented with 10 mM
-glycerol phosphate and 50 g/ml of ascorbic acid. Cultures
were then fixed at days 7 and 14 using 100% ethanol and
assessed for alkaline phosphatase activity and mineral deposi-
tion with Fast Red TR/Naphthol AS-MX phosphate (Sigma) or
40 mM Alizarin Red (Sigma) staining, respectively. Image anal-
ysis was performed using FIJI (62).
Quantitative real-time PCR
Total RNA was collected from cells and tissue samples using
TRIzol (Invitrogen) following the manufacturer’s protocol.
One g of RNA was then reversely transcribed using an iScript
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cDNA synthesis kit (Bio-Rad). Two microliters of cDNA were
amplified under standard PCRconditions using iQSYBRGreen
Supermix (Bio-Rad). All cDNA samples were run in triplicate,
averaged, and normalized to endogenous -actin expression
levels. Primer sequences were designed using Primer-BLAST
(NCBI) and are available upon request.
Cell lysis and immunoblotting
For signaling experiments, osteoblasts were cultured to near
confluence in -MEM containing 10% FBS. Cells were then
starved in -MEM containing 0.5% FBS overnight to reduce
endogenous cellular activity prior to stimulation.ActivinA,AB,
and B (R&D Systems) were added to the medium for a final
concentration of 20 ng/ml. ACVR2B/Fc was supplemented to a
final concentration of 50 ng/ml. Whole cell lysates were then
collected at appropriate time points in lysis buffer (50 mM Tris
(pH 7.4), 150 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1% Triton
X-100, and 10% glycerol). Protein concentrations were mea-
sured by BCA Protein Assay (Pierce) and 15 g of total protein
were loaded into each lane using a mini-SDS-PAGE system
(Bio-Rad). Following electrophoresis, proteinswere transferred
to a PDVFmembrane using aMiniTrans-blotCell System (Bio-
Rad). Membranes were then blocked using 5% BSA at room
temperature for 1 h and then incubated with the antibody of
interest (Cell Signaling) at 4 °C overnight. Protein signal was
detected using secondary antibodies conjugatedwith horserad-
ish peroxidase. Chemiluminescence of bound antibody was
produced by Supersignal West Femto Substrate (Pierce) and
captured by Gel Doc XR System (Bio-Rad). Blot analysis was
performed using Image Lab (Bio-Rad).
Mechanical testing
Femurs were harvested from 12-week-old control and
ACVR2A male mice. Soft tissue was then cleared from the
femur and placed on a custom three-point bending apparatus
with a span of 5.3 mm. After a preload of 0.3 newton, the femur
was subjected to force in displacement control at 0.1mm/s until
fracture was achieved (Bose Electroforce 3100). Bone hydration
was maintained throughout the testing period using PBS.
Force-displacement data and micro-CT imaging was analyzed
using a custom MATLAB (MathWorks) program similar to
others (63).
Statistical analysis
All values are shown as mean  S.E. Statistical significance
between comparable groups was assessed using Student’s t test
with an assigned significance level () of 0.05.
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